ILA
ISLAND PHARMACEUTICALS LIMITED
$0.3900
▼ -2.50%
Market cap
$115M
Turnover
$47,463
Last price
$0.3900
Day change
-2.50%
Announcements
20
Range, past year
Open 0.400 · Low 0.130 · Now 0.390 · High 0.630
Open ILA in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
ILA momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
28/100
Wyckoff phase
Downtrend3d
Trend stage
Breakdown
1 Day
-2.5%
1 Week
-7.1%
1 Month
-11.4%
1 Year
-4.9%
RSI
33
Avg daily range
3.6%
ISLAND PHARMACEUTICALS LIMITED scores 28 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 3 trading days. The weekly timeframe reads Accumulation, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -20.8%
- Thin liquidity
- Risk rating: High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsILA announcements
Recent price-sensitive releases.
- 2026-08-31 Pivotal Marburg data secured for Galidesivir FDA pathway Progress Report
- 2026-08-26 Preliminary Final Report Preliminary Final Report
- 2026-08-21 Island boosts Galidesivir supply as Ebola surges Progress Report
- 2026-07-30 Quarterly Appendix 4C and Activities Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-13 Texas Biomed SOW accelerates pivotal FDA pathway
- 2026-07-08 Investor Presentation - Ebola Clinical Program
- 2026-07-07 Galidesivir approved for treatment use in in Ebola epidemic
More Health Care stocks
Most traded in the same sector.